CD8A and neoplasm: Multiple studies have found that T cells expressing PD-1 depletion markers are enriched in CD8+ TILs that recognize the tumor reactivity of autologous tumor cells: the high abundance of CD8+ TILs expressing the failure marker PD-1 before or early in treatment predicts the clinical benefit of treatment with ICIs (67).